Product Images Eribulin Mesylate

This is a dosage and use instruction for Eribulin Mesylate Injection, a sterile solution containing 1 mg of eribulin mesylate in 2 mL of solution. Each mL of the solution contains 0.5 mg of eribulin mesylate. The solution also contains dehydrated alcohol and water for injection. It should be stored at 20° to 25°C. It is for intravenous use as a cytotoxic agent and comes in single-dose vials labeled with NDC 70095-080-01. Unused portions should be discarded. The product is distributed by Sun Pharmaceutical Industries, Inc.*

This is an updated overall survival analysis for Study 1, comparing patients taking Eribulin Mesylate with a control group. The graph shows the proportion of patients alive over time in months, with a higher survival rate observed for patients taking Eribulin Mesylate compared to the control group. The number of patients at risk at different time points is also provided, indicating the number of patients who were still participating in the study.*

This is a Kaplan-Meier analysis comparing overall survival in the Liposarcoma Stratum in Study 2 between Eribuline Mesylate and Dacarbazine. The graph shows survival time in months with the number of subjects at risk in each group indicated at specific time points. The analysis provides insights into the effectiveness of Eribulin Mesylate versus Dacarbazine for this specific stratum.*

This text is a description of a sterile solution called Eribulin Mesylate for intravenous use. It provides guidance on storage conditions, dosage information, and cautions regarding its use as a cytotoxic agent. The solution should be stored at room temperature, and instructions specify not to freeze or refrigerate it. Additional details such as NDC number, expiration date, and the manufacturer are also included.*